Genmab Announces IFM, HOVON and Janssen Achieve Positive Topline Results in Second Part of Phase 3 CASSIOPEIA Study of Daratumumab in Multiple Myeloma at Pre-planned Interim Analysis

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Stacey Gandler
Brand Nourishment

Matt Turner
Patient Affordability

Bud Bilanich
Success Coach

Suma Ramadas, PhD
Medical Affairs

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Amy Giles
Increasing Engagement